Inventor · disambiguated record
Patrick Haslett
Also filed as: HASLETT PATRICK · HASLETT PATRICK ANTHONY JOHN
4 granted patents·12 pending applications·1 citations·filing 2012–2023
56Inventor score
Top patents by PatentIndex Score
16 records- 0182US11034957B2Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·1 cites·30 claims
- 0263US2024271144A1Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0363US2022002724A1AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0457US2022228151A1Carboxypeptidase B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0554US11059906B2Anti-CCL2 and anti-LOXL2 combination therapy for treatment of sclerodermaSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Jul 13, 2021·0 cites·4 claims
- 0654US2022228144A1SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0752US2023040920A1Compositions and methods for silencing dnajb1-prkaca fusion gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0851US2015158942A1Anti-ccl2 antibodies for treatment of sclerodermaSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Application pending·0 cites
- 0950US2018036386A1Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiiaSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
- 1050US2018179275A1Anti-ccl2 antibodies for treatment of sclerodermaSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
- 1148US2015313971A1Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiiaSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Application pending·0 cites
- 1245US2016289319A1Anti-ccl2 antibodies for treatment of sclerodermaSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Application pending·0 cites
- 1341US10639356B2Treatment of cognitive impairment of mucopolysaccharidosis type IIIA by intrathecal delivery of heparan N-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted May 5, 2020·0 cites·14 claims
- 1440US10578624B2Determination of glycosaminoglycan levels by mass spectrometrySHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Mar 3, 2020·0 cites·11 claims
- 1537US2017131293A1Biomarkers for sanfilippo syndrome and uses thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Application pending·0 cites
- 1635US2013121984A1Biomarkers for sanfilippo syndrome and uses thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Patrick Haslett files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →